We are international

Mozobil (plerixafor injection) is approved by the United States Food and Drug Administration (FDA) to be used with another agent granulocyte-colony stimulating factor (G-CSF), to mobilize stem cells into the peripheral blood for collection and subsequent autologous transplantation in patients with myeloma.


01.22.10   Mozobil Tip Card
What it is, how it works, administration, benefits and risks on one easy to understand card.

08.05.09   International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
Published in Leukemia (2009), 1–9

08.01.09   Myeloma Today Summer 2009

Articles include:

* Plerixafor and Transplantation in Myeloma
* Phase II Study of Carfilzomib in Patients with Relapsed Myeloma
* IMWG Studies Patients Who Have Exhausted Their Treatment Options
* 2009 Kyle Award Given to Prof. Jean-Luc Harousseau
* Dr. Brian G.M. Durie Honored for Lifetime of Achievement in Myeloma

News about Mozobil
12.17.08   Myeloma Minute
December 17, 2008

01.20.10   Genzyme's Informational Website on Mozobil